R Ketamine

Price range: $230.00 through $1,500.00

Formula	C₁₃H₁₆ClNO
Molar mass	237.73 g·mol⁻¹

R Ketamine, also known as (R) Ketamine, is one of the stereoisomers of ketamine, a well-known anesthetic and emerging treatment for depression and other mood disorders. Unlike the more commonly used racemic mixture (which contains equal parts of R- and S-enantiomers), R Ketamine is a single enantiomer that has garnered interest for its unique pharmacological profile.

Quantity

Clear

SKU: N/A Category: Ketamine

R Ketamine: An Overview

Chemical Background

Ketamine is a chiral molecule, meaning it has two mirror-image forms: R- and S-enantiomers. These enantiomers differ slightly in their chemical structure, which can influence their potency, duration of action, and side effect profiles. R-Ketamine is the (R)-enantiomer, whereas S-Ketamine is the (S)-enantiomer.

Pharmacological Profile

Research suggests that R-Ketamine may have antidepressant effects comparable to or even greater than S-Ketamine, but with potentially fewer side effects such as dissociation or hallucinations. It appears to act primarily on NMDA receptors in the brain but may also influence other neural pathways involved in mood regulation.

Potential Benefits

Rapid antidepressant effects: R-Ketamine has shown promise in preclinical and clinical studies for providing quick relief from depressive symptoms.
Reduced side effects: Some evidence indicates that R-Ketamine might cause fewer psychotomimetic effects compared to S-Ketamine or racemic ketamine.
Longer-lasting effects: Certain studies suggest that R-Ketamine may produce more sustained antidepressant benefits.

Current Research and Clinical Use

While S-Ketamine (marketed as Spravato) has gained FDA approval for treatment-resistant depression, R-Ketamine remains largely experimental. Ongoing research aims to better understand its efficacy, safety profile, and potential advantages over existing treatments.

Conclusion
R-Ketamine represents a promising frontier in the development of fast-acting antidepressants with fewer adverse effects. Continued research will clarify its role in psychiatric treatment and whether it can become a standard therapy in the future.